Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Breast Cancer

Trial Name: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study-evaluating everolimus with endrocrine therapy.

Protocol ID: SWOG 1207

Eligibility:

  • Patients must have a histologically confirmed diagnosis of invasive breast carcinoma with positive estrogen and/or progesterone receptor status, and negative HER-2, for whom standard adjuvant endocrine therapy is planned.
  • Patients must not have metastatic breast cancer (Stage IV disease).
  • Patients must have completed either breast conserving surgery or total mastectomy, with negative margins and appropriate axillary staging.
  • Patients must not be receiving or planning to receive trastuzumab.
  • Patients must meet required laboratory values
  • Patients must be able to take oral medications
  • No other prior malignancy is allowed except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer or other cancer for which the patient has been disease-free for 5 years.

Patients must not be pregnant or nursing due to the potential for congenital abnormalities, and the potential of this regimen to harm nursing infants.

Enrollment: • About 3500 people will take part in this study at several medical centers.

Benefits:

Taking part in this study may or may not make your health better.  While doctors hope the study drug will be more useful against cancer compared to the usual treatment, there is no proof of this yet.  We do know that the information from this study will help doctors learn more about blinded drug as a treatment for cancer.  This information could help future cancer patients.

Contact:

These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Aspirus Regional Cancer Center Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353, or Langlade Cancer Center Research Nurse Debra Witman @ 715-623-9587.

Created: Mar 18, 2014

Updated: May 21, 2014

« Return to Trials